Skip to Main Content

INFORMATION FOR

Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003

Conditions

Kidney | Phase I

Phase I

What is the purpose of this trial?

This is an open label, multi-institutional, single arm study of dose escalation phase Ib cohort, followed by a phase II cohort of anti-PD-1 antibody MK-3475 in combination with bevacizumab. No randomization or blinding is involved.

  • Trial with
    Merck Sharp & Dohme LLC
  • Start Date
    09/01/2022
  • End Date
    12/05/2019

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    01/24/2023
  • Study HIC
    #2000029978